Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

The human body naturally produces opioid-like substances, such as endorphins, which block the perception of pain and increase the feeling of well-being. Similarly, opioid drugs, including morphine or ...

Activation of the body’s opioid system may be required for ketamine’s antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker ...

Quick-acting targeted therapies with minimal side effects are an urgent need for the treatment of anxiety-related disorders. While delta opioid receptor (DOP) agonists have shown 'anxiolytic' or ...

INDIANAPOLIS, March 28, 2023 — There’s been a recent push in the U.S. to make naloxone — a fast-acting opioid antidote — available without a prescription. This medication has saved lives, but it’s ...

BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this ...